

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (CD-144) UMBRALISIB


PRONUNCIATION um" bra lis' ib

THERAPEUTIC CLAIM Treatment of cancer and B-cell related disorders

CHEMICAL NAMES

1. 4*H*-1-Benzopyran-4-one, 2-[(1*S*)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-
2. 2-[(1*S*)-1-{4-amino-3-[3-fluoro-4-(propan-2-yloxy)phenyl]-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl}ethyl]-6-fluoro-3-(3-fluorophenyl)-4*H*-1-benzopyran-4-one

STRUCTURAL FORMULA



MOLECULAR FORMULA C₃₁H₂₄F₃N₅O₃

MOLECULAR WEIGHT 571.5

TRADEMARK None as yet

SPONSOR TG Therapeutics, Inc.

CODE DESIGNATIONS TGR-1202 base, RP-5264

CAS REGISTRY NUMBER 1532533-67-7

UNII 38073MQB2A

WHO NUMBER 10350

gbk